Delivery Order SPE2DB20D3104-SPE2DB22FV4Y8
- Not listed
- This federal contract award from the Defense Logistics Agency (DLA) is a delivery order to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of Humulin R 500 Unit/mL Kwikpen 3mL, a specialty medication used for diabetes management. The contract has a ceiling value of $12,619.21 and a completion date of April 3, 2024. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which holds a significant $999,999,999.00 Indefinite Delivery Contract...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of Humulin R 500 unit/mL Kwikpen 3mL. The contract has a ceiling value of $9,036.66 and a performance period ending on July 11, 2025. This award is not set-aside and represents an open competition. Amerisourcebergen holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of Humulin R 500 unit/mL Kwikpen 3mL. The contract has a ceiling value of $3,627.48 and a performance period through April 26, 2023. It is a firm-fixed-price delivery order contract and was not set aside for any specific business category. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which holds a significant...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, Corporate Office Division, a major pharmaceutical distributor, for the supply of HUMULIN R 500 UNIT/ML KWIKPEN 3ML. The award has a ceiling value of $3,591.53 and an ultimate completion date of August 5, 2024. This delivery order is part of a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA Troop Support Medical, valued up to $999,999,999 through December 2025,...
- This is a delivery order awarded to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., by the Defense Logistics Agency (DLA) for the supply of Humulin R 500 Unit/mL Kwikpen 3mL. The $10,586.92 firm fixed price contract has a completion date of June 17, 2022. Amerisourcebergen, a major pharmaceutical distributor, holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical to provide a comprehensive range of pharmaceutical products and medical supplies to...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $9,660.01 firm fixed-price contract is for the supply of Humulin R 500 Unit/mL Kwikpen 3mL, a medication used to treat diabetes. The contract has an ultimate completion date of March 4, 2025 and is not designated as a set-aside. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of Humulin R 500 Unit/mL Kwikpen, a diabetes medication, with a ceiling value of $6,434.52 and a performance period through May 2025. The contract is a firm fixed-price, non-set-aside award, indicating open competition. AmerisourceBergen Drug Corp holds a larger Indefinite Delivery Contract (IDC) with DLA Troop...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor, for the supply of Humulin R 500 Unit/ML Kwikpen 3ML, a specialized insulin medication product. The fixed-price delivery order has a ceiling value of $6,256.95 and a completion date of August 13, 2024. This order is not associated with a set-aside program. As a prominent supplier of pharmaceutical and medical products to the federal government,...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp for the supply of Humulin R 500 unit/mL Kwikpen 3mL. The $7,269.32 firm fixed price contract has a period of performance through March 24, 2023. AmerisourceBergen, a major pharmaceutical distributor, holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical to provide a comprehensive range of pharmaceutical products and medical supplies to support military...
- This is a Delivery Order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of Humulin R 500 Unit/mL Kwikpen 3mL, a specialty insulin medication. The total ceiling value of the contract is $5,784.00, with a performance period through December 5, 2024. Amerisourcebergen holds a larger $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
- SPE2DB20D3104Indefinite Delivery Contract
- SPE2DB20D3104-SPE2DB22FV4Y8Delivery Order
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Humulin R 500 unit/mL Kwikpen 3 mL. The contract has a ceiling value of $3,379.68 and an ultimate completion date of February 9, 2022. This award is not designated with a set-aside requirement, indicating open competition. AmerisourceBergen Drug Corp is a subsidiary of Cencora, Inc., which holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through December 2025. This IDC serves as the primary vehicle for AmerisourceBergen to deliver a comprehensive range of pharmaceutical products and medical supplies to support military treatment facilities, veterans' healthcare programs, and other federal medical institutions. The company also maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at up to $750,000 through May 2024, for similar medical products and prescription drugs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.4k | 2/8/22 |